Skip to main content

Research Repository

Advanced Search

Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer’s disease

Kerr, Fiona; Sofola-Adesakin, Oyinkan; Ivanov, Dobril K.; Gatliff, Jemma; Gomez Perez-Nievas, Beatriz; Bertrand, Hélène C.; Martinez, Pedro; Callard, Rebecca; Snoeren, Inge; Cochemé, Helena M.; Adcott, Jennifer; Khericha, Mobina; Castillo-Quan, Jorge Iván; Wells, Geoffrey; Noble, Wendy; Thornton, Janet; Partridge, Linda

Authors

Oyinkan Sofola-Adesakin

Dobril K. Ivanov

Jemma Gatliff

Beatriz Gomez Perez-Nievas

Hélène C. Bertrand

Pedro Martinez

Rebecca Callard

Inge Snoeren

Helena M. Cochemé

Jennifer Adcott

Mobina Khericha

Jorge Iván Castillo-Quan

Geoffrey Wells

Wendy Noble

Janet Thornton

Linda Partridge



Abstract

Nrf2, a transcriptional activator of cell protection genes, is an attractive therapeutic target for the prevention of neurodegenerative diseases, including Alzheimer’s disease (AD). Current Nrf2 activators, however, may exert toxicity and pathway over-activation can induce detrimental effects. An understanding of the mechanisms mediating Nrf2 inhibition in neurodegenerative conditions may therefore direct the design of drugs targeted for the prevention of these diseases with minimal side-effects. Our study provides the first in vivo evidence that specific inhibition of Keap1, a negative regulator of Nrf2, can prevent neuronal toxicity in response to the AD-initiating Aβ42 peptide, in correlation with Nrf2 activation. Comparatively,
lithium, an inhibitor of the Nrf2 suppressor GSK-3, prevented Aβ42 toxicity by mechanisms independent of Nrf2. A new direct inhibitor of the Keap1-Nrf2 binding domain also prevented synaptotoxicity mediated by naturally-derived Aβ oligomers in mouse cortical
neurons. Overall, our findings highlight Keap1 specifically as an efficient target for the reactivation of Nrf2 in AD, and support the further investigation of direct Keap1 inhibitors for the prevention of neurodegeneration in vivo.

Citation

Kerr, F., Sofola-Adesakin, O., Ivanov, D. K., Gatliff, J., Gomez Perez-Nievas, B., Bertrand, H. C., Martinez, P., Callard, R., Snoeren, I., Cochemé, H. M., Adcott, J., Khericha, M., Castillo-Quan, J. I., Wells, G., Noble, W., Thornton, J., & Partridge, L. (2017). Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer’s disease. PLoS Genetics, 13(3), Article e1006593. https://doi.org/10.1371/journal.pgen.1006593

Journal Article Type Article
Acceptance Date Feb 6, 2017
Online Publication Date Mar 2, 2017
Publication Date Mar 2, 2017
Deposit Date Mar 3, 2017
Publicly Available Date Mar 9, 2017
Journal PLOS Genetics
Print ISSN 1553-7390
Electronic ISSN 1553-7404
Publisher Public Library of Science
Peer Reviewed Peer Reviewed
Volume 13
Issue 3
Article Number e1006593
DOI https://doi.org/10.1371/journal.pgen.1006593
Public URL http://researchrepository.napier.ac.uk/Output/692163
Contract Date Mar 3, 2017

Files

Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer’s disease (6.5 Mb)
PDF

Copyright Statement
Copyright: © 2017 Kerr et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.







You might also like



Downloadable Citations